LIPO Lipella Pharma: Enterprise Value to EBITDA Ratio
Lipella Pharmaceuticals (LIPO) management is betting on the development of targeted drug delivery systems for the therapy of inflammation and urological pathologies. The price action based on the EV/EBITDA metric is . The company strictly adheres to bioethical standards and environmental regulations, reducing harmful emissions in its laboratories. The business relies on an autonomous production cycle, which makes it resilient to global crises and transforms it into a reliable defensive asset.
Comprehensive metric breakdowns and analytics for lipella.com (LIPO)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Lipella Pharmaceuticals|LIPO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipella Pharmaceuticals, Inc.|LIPO - Company Debts|Debts to Book Capitalization Lipella Pharma|LIPO - Long-Term Debt Volume|Company Short-Term Debt Lipella Pharmaceuticals|Quick Ratio lipella.com
- financial results and valuation multiples details:
LIPO - Company Net Income|Expected Profit Lipella Pharmaceuticals|LIPO - Price to Earnings Ratio|Future Price to Earnings Lipella Pharmaceuticals|LIPO - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Lipella Pharma|LIPO - Operating profit EBITDA|Net earnings per share for the last 12 months Lipella Pharmaceuticals|LIPO - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months lipella.com|LIPO - Earnings per share trend in current year|Earnings growth forecast for next year Lipella Pharmaceuticals
Summary company analytics:Lipella LIPO
Lipella Pharmaceuticals' narrow specialization in FDA-protected orphan drugs creates a sustainable market barrier. The EV/EBITDA metric correlates the total enterprise value with operating profit before depreciation and interest, revealing the real value of assets relative to their ability to generate cash flow. By analyzing the historical EV/EBITDA trend of Lipella Pharmaceuticals, an investor can quickly identify leverage risks or margin compression.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MannKind Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Amphastar - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pacira Corp PCRX|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio TBPH (theravance.com)|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA scPharma SCPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNXP (Tonix Pharmaceuticals Holding)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BioHarvest Sciences Inc. - EV/EBITDA Multiple|EXOZ - EV/EBITDA Multiple|ORMP (oramed.com) - Enterprise Value to EBITDA Ratio|Entera Bio - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|abvcpharma.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CPIX|QNTM (Quantum BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FGEN (FibroGen Corp)|EV/EBITDA Multiple Telomir Pharmaceuticals Corp TELO|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SNYR (Synergy CHC Corp)|rallybio.com (RLYB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Lexaria Bioscience Corp.|PULM (Pulmatrix Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Pheton|EV/EBITDA Multiple APM|Enterprise Value to EBITDA Ratio lyratherapeutics.com LYRA|EV/EBITDA Multiple IBO (Impact BioMedical)|TNF Pharmaceuticals Inc. (TNFA) - Company Value to EBITDA|YCBD: Enterprise Value to EBITDA Ratio|PRFX - EV/EBITDA Multiple|CYTO (altamiratherapeutics.com) - Enterprise Value to EBITDA Ratio|OPTN: Enterprise Value to Operating Income Before Depreciation Ratio|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|Enterprise Value to EBITDA Ratio Qilian International Corp QLI|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|EV/EBITDA Multiple tffpharma.com TFFP
